Clinical trials: Impulse Control Disorders
Intermittent Explosive Disorder
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder
This is a multicenter, randomized, double-blind, placebo-controlled study to evaluate AVP-786 for the treatment of Intermittent Explosive Disorder (IED).
- Trial name
- NCT03420222
- Testing
- AVP-786
- Where
- 9 sites in United States
- Volunteers
- 10 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.